FDA reviews depression drugs–Intense or Cautious? WashPost/ NYT/ Herald

FDA reviews depression drugs–Intense or Cautious? WashPost/ NYT/ Herald Wed, 29 Oct 2003 The Washington Post correctly reports: “The association between antidepressants, particularly the selective serotonin reuptake inhibitors (SSRIs), and suicide has been controversial since the first SSRI, Prozac, came on the market in the late 1980s.” But stakeholders in…

Paxil induced suicides in US quantified_Glaxo Faces criminal action in UK over "suicide" pills_Times

Paxil induced suicides in US quantified_Glaxo Faces criminal action in UK over “suicide” pills_Times Mon, 7 Jun Law enforcement is finally catching up with drug companies who, for years, concealed evidence of a drug-related suicide risk for some children and adults who take an antidepressant. The law requires the companies…

Evidence of Drug Harm that the FDA Sought to Suppress

Evidence of Antidepressant Harm that the FDA Sought to Suppress from FDA’s Public Advisory Committee Meeting on February 2 Evidence was presented on February 2 at AHRP’s press briefing by the following scientists: David Healy, MD, Director of the North Wales Department of Psychological Medicine and Visiting Professor, University of…

Selling Sickness: Pharma Industry Turning Us All Into Patients

Selling Sickness: Pharma Industry Turning Us All Into Patients Mon, 12 Sep 2005 Related Link: Selling Sickness Prologue Selling Sickness: How the World’s Pharmaceutical Companies Are Turning Us All Into Patients, by Ray Moynihan, an international health journalist, and Alan Cassels, a pharmaceutical policy researcher, is likely to become a…

Advisory Committee tells FDA: strengthen warnings on SSRI drug labels now

Advisory Committee tells FDA: strengthen warnings on SSRI drug labels now Wed, 4 Feb 2004 On February 2, more than 60 families and children from all across America testified at a public FDA advisory committee hearing describing (in 2 minutes) how their children suffered drug-induced harm after being prescribed an…

Daniel Troy Legacy: Public Virtually Defenseless against Unsafe Drugs

Daniel Troy Legacy: Public Virtually Defenseless against Unsafe Drugs Thu, 18 Nov 2004 The Associated Press reports that at a Congressional hearing today, Dr. David Graham a drug safety expert at the FDA told the Senate Finance Committee that the public is “virtually defenseless” if another medication such as Vioxx…

Antidepressant Controversy: Media Conflicts of Interest – New York Times

Antidepressant Controversy: Media Conflicts of Interest – New York Times Thu, 25 Mar 2004 FDA’s advisory warning about antidepressant drugs received wide press coverage nationally. But few in the national media mentioned conflicts of interest as the obstacle to disclosure of evidence showing these drugs’ adverse effects. Among the few…

Psychiatry and Preschoolers

Psychiatry and Preschoolers Tue, 1 Jul 2003 There was a time that doctors followed the precautionary “do no harm” principle when prescribing drugs. But the practice of medicine has changed radically as physicians have increasingly become financially tied to the pharmaceutical industry. Among psychiatrists it is difficult to find one…

Infomail Archive 2005

Infomail 2005 News Stories on Human Research Protection and Commentary by Vera Hassner Sharav Subscribe to the AHRP infomail list Dec 16: Drugs, Devices & Doctors – NYT Paul Krugman Dec 11: Scientific Fraud & Corruption on Both sides of Atlantic: Merck / Proctor & Gamble Dec 11: Gov Accountability…

2 letters Re: Dr. Nemeroff Failure to Disclose Conflicts of Interest_WSJ

Success in academic psychiatry is not measured in the improvement of patients' mental health, but rather in quantifiable commercial tender.How many grants one brings to the university, how many publications one churns out each year, and how many corporate and professional advisory boards one serves on–and how much money one…